Clinical Trial Detail

NCT ID NCT03202940
Title A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Alectinib + Cobimetinib

Age Groups: adult senior

Additional content available in CKB BOOST